Clinical Trials for Non-Small Cell Lung Cancer

A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates the safety and efficacy of HER3-DXd, an antibody-drug conjugate targeting HER3, in patients with metastatic or unresectable NSCLC, including those with EGFR and KRAS-G12C mutations after prior therapy. The treatment aims to address various genetic subgroups by delivering a cytotoxic payload that induces DNA damage specifically in cancer cells.

ClinicalTrials.gov ID: NCT03260491

An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab (MK-3475) in Combination With Sacituzumab Govitecan Versus MK-3475 Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer (KEYNOTE D46/EVOKE-03)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adult patients with metastatic non-small cell lung cancer (NSCLC) and a PD-L1 tumor proportion score of 50% or greater, comparing pembrolizumab, a PD-1 checkpoint inhibitor, combined with sacituzumab govitecan, a Trop-2 targeted antibody-drug conjugate, versus pembrolizumab monotherapy. Eligible patients must not have had prior systemic therapy for metastatic NSCLC and should not require targeted therapies for EGFR, ALK-1, or ROS-1 mutations.

ClinicalTrials.gov ID: NCT05609968

A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination With Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination With Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial evaluates subcutaneous amivantamab combined with lazertinib as first-line treatment or with platinum-based chemotherapy as second-line treatment for adult patients with advanced or metastatic NSCLC having common EGFR mutations (Ex19del or Ex21 L858R). Amivantamab targets EGFR and MET receptors, potentially overcoming resistance, and is used with lazertinib, an EGFR tyrosine kinase inhibitor, or chemotherapy including carboplatin and pemetrexed.

ClinicalTrials.gov ID: NCT06667076

A Single-Arm Phase 2 Study of Daratumumab Subcutaneous (SC) in Previously Treated STK11/LKB1 Mutated Non-small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial targets adult patients with metastatic or unresectable STK11/LKB1 mutated non-small cell lung cancer who have progressed following prior therapies, using daratumumab, a CD38-targeting monoclonal antibody, administered subcutaneously to evaluate its efficacy in improving overall response rate.

ClinicalTrials.gov ID: NCT05807048

Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves patients aged 18 and older with advanced solid tumors, including NSCLC, melanoma, pancreatic, and ovarian cancers, who have progressed after standard treatments or are treatment-naïve. It evaluates the safety and efficacy of ONC-392, an anti-CTLA-4 monoclonal antibody, alone and combined with pembrolizumab to determine appropriate dosing for future studies.

ClinicalTrials.gov ID: NCT04140526

Beamion LUNG-1: An Open Label, Phase I Dose Escalation Trial, With Dose Confirmation and Expansion, of Zongertinib (BI 1810631) as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial investigates zongertinib (BI 1810631), a tyrosine kinase inhibitor targeting HER2 aberrations, as monotherapy in adult patients with advanced or metastatic non-hematologic solid tumors, particularly non-small cell lung cancer with specific HER2 mutations. It focuses on individuals who have progressed after previous treatments or are treatment-naive, in a dose escalation and expansion study.

ClinicalTrials.gov ID: NCT04886804

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial involves adults with advanced or metastatic solid tumors who will receive Lattice Radiation Therapy (LRT) as an experimental treatment, with a focus on evaluating its effectiveness compared to standard stereotactic body radiation therapy (SBRT) in controlling extra-cranial soft tissue metastases and influencing immune cell infiltration.

ClinicalTrials.gov ID: NCT05837767

LUNAR-2: Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab and Platinum-based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: The trial targets patients with stage 4 metastatic non-small cell lung cancer (NSCLC) who have an ECOG performance status of 0-1 and no prior systemic treatment, evaluating the effectiveness of Tumor Treating Fields (TTFields), which disrupt cancer cell division, in combination with pembrolizumab, an immune checkpoint inhibitor, and platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT06216301

A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with advanced solid malignancies, evaluating the safety and efficacy of the PARP inhibitor AZD5305, both alone and combined with agents like Paclitaxel and Trastuzumab Deruxtecan, showing promising response rates and reduced hematologic toxicity.

ClinicalTrials.gov ID: NCT04644068

A Phase Ib Study of AZD9291 (Osimertinib) and BC2059 (Tegavivint) as First-Line Therapy in Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial involves adult patients with metastatic EGFR-mutant non-small cell lung cancer, investigating the combination of osimertinib, an EGFR tyrosine kinase inhibitor, and tegavivint, a Wnt/β-catenin pathway inhibitor, to assess safety, tolerability, and preliminary efficacy.

ClinicalTrials.gov ID: NCT04780568